This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
OK
#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 17 °C Sunday 9 August, 2020
Advertisement

Pfizer to create up to 250 construction jobs

Pfizer is expanding its plants in Dublin and Cork to produce pharmaceuticals to deal with some of the most difficult to cure diseases.

Image: Eamonn Farrell/Photocall Ireland

PHARMACEUTICAL GIANT PFIZER is to invest €100 million in two manufacturing sites in Ireland, creating an estimated 250 construction jobs.

The company said it is expanding two sites – one in Clondalkin in Dublin and the other in Ringaskiddy in Cork – to produce drugs which will deal with some of the most devastating and difficult to cure diseases.

Construction at the Dublin site is to begin soon, with 140 jobs to be created over the next year with a peak of 250 jobs altogether. The factory will be opened in 2015.

The €23 million euro investment in Ringaskiddy will create new equipment and technology to work on new clinical products.

Minister for Jobs Richard Bruton said the announcement was “confirmation that we are taking the right steps to ensure that Ireland is a key location for companies like Pfizer to expand and grow their business.”

Pfizer opened its first factory in Ireland in the 1970s and currently employs an estimated 3,200 people across six sites in Ireland. The company cut 6,000 jobs worldwide in 2010, with 200 people made unemployed from its plant in Newbridge in Kildare.

Read: Jobs expo targets skilled Irish workers to help with Christchurch rebuild >

Read: Hewlett Packard is cutting 280 jobs at its Dublin office >

Read: Ulster Bank to close 39 branches >

  • Share on Facebook
  • Email this article
  •  

Read next:

COMMENTS (24)